Inhalable Perfluorocarbon RNA Nanocapsules Bypass Immune Clearance While Targeting Lung Epithelial and Lung Tumor...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Lung metastases treatments like chemotherapy and surgery have limitations, including recurrence and side effects.
• Inhalation-based RNA therapy offers a potential alternative to reduce systemic exposure and first-pass metabolism.

Purpose of the Study:

• To develop and evaluate an inhalable perfluorocarbon nanocapsule system for targeted delivery of RNA interference therapeutics to lung metastases.

Main Methods:

• Development of aerosolized perfluorocarbon nanocapsules for RNA delivery.
• In vivo administration and assessment of nanocapsule uptake, retention, and immune response in lung tissues.
• Evaluation of therapeutic efficacy in reducing metastatic tumor burden and enhancing anti-tumor immunity.
• Molecular dynamics simulations to assess nanocapsule stability and the role of excipients.

Main Results:

• Nanocapsules demonstrated effective uptake by lung and tumor cells with prolonged retention (>48h).
• Minimal inflammatory response and negligible off-target organ accumulation were observed.
• The treatment significantly reduced metastatic tumor burden and enhanced anti-tumor immunity, nearly doubling lifespans after three doses.
• Simulations suggested stearate and vitamin E can inhibit nanocapsule agglomeration, improving shelf-life.

Conclusions:

• Inhalable perfluorocarbon nanocapsules represent a non-invasive, biocompatible platform for effective lung tumor targeting.
• This delivery system overcomes limitations of current lung metastasis treatments.
• The technology shows significant promise for improving cancer therapy outcomes.